Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03119467 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy Study of RP4010, in Patients With Relapsed or Refractory Lymphomas
A Phase 1 study, sponsored by Rhizen Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT03119467 is a Phase 1 study that was terminated before completion, run by Rhizen Pharmaceuticals. The registered enrollment target is 21 participants.
The verdict
NCT03119467, a Phase 1 study, was terminated before completion, sponsored by Rhizen Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
A Phase I/Ib, Study to Evaluate Safety and Efficacy of RP4010, in Patients with Relapsed or Refractory Lymphomas
Interventions
- DRUG RP4010
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2017-05-11 |
| Est. Completion | 2019-12-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03119467
The ClinicalTrials.gov registry entry for NCT03119467 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rhizen Pharmaceuticals, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RP4010 is the first listed.
NCT03119467 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03119467 about?
NCT03119467 is a clinical study titled "Safety and Efficacy Study of RP4010, in Patients With Relapsed or Refractory Lymphomas". A Phase I/Ib, Study to Evaluate Safety and Efficacy of RP4010, in Patients with Relapsed or Refractory Lymphomas
What is the current status of trial NCT03119467?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2017-05-11. Estimated completion is 2019-12-19.
What interventions are being tested in trial NCT03119467?
The interventions under investigation include: RP4010 (DRUG).
Who is sponsoring clinical trial NCT03119467?
This trial is sponsored by Rhizen Pharmaceuticals, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.